On 4th February, annually, the whole world takes a moment to commemorate the deadly disease, cancer and lives it has cost. In response to the ailment, oncologists around the world spend sleepless nights trying to figure out the best treatment to relieve the patient’s suffering while seeking for a cure.
Seattle Genetic is among the few companies that have dedicated their abilities to assist the cancer patients since 1998. Seattle’s founder, Clay Siegall was interested in the field of medicine and this saw him joining a medical school. Having lost a family member to the killer disease, Siegall felt the need to research for better ways to treat the ailment, and that’s how Settle Genetics was established.
With time, Siegall’s company has managed to generate enough cash to boost its main objective which is supporting the cancer patients in the best way possible. Selling its own drugs is one way in which the company generates cash. Besides, the company earns great revenue from partnerships and licensing of technologies they often launch.
According to Clay Siegall, the company’s President, life in business has not always been a bed of roses for his team. However, whenever a challenge emerges, Clay and his team implement a strategy to by-pass it for the sake of survival. The company seeks for the services of the best sales persons who are passionate in the field of biotech which means more and more customers. Seattle Genetics has popularly been known for its referrals mode of business, but Clay boasts that his team is blessed with great negotiators who are always behind closed doors striking significant deals.
About Clay Siegall
Today, Clay Siegall is the President, CEO, as well as the chairman of the board of his company. The hardworking CEO has held the CEO position in the company since 2002 with about two decades experience in the innovations and leadership.
Clay graduated from the University of Maryland with a B.S. in Zoology. Also, the hardworking specialist earned a Ph.D. in Genetics from the prestigious George Washington University. A few years after graduating from college, Clay got his first employment as a Senior Research Investigator at the Bristol-Myers Squibb Institute.
After few years of success, Clay was promoted to become the Institute’s Principal Scientist. Later on, Clay joined the National Cancer Institute as the Staff Fellow and Biotechnology Fellow. In 1998, Clay Siegall founded Seattle Genetics, a company that he has continued to work tirelessly and judging from his record, and it is clear that he does not intend to slow down anytime soon.